Scientists have isolated a compound from a plant species in Southeast Asia that triggers triple-negative breast cancer cells to destroy themselves—a finding that matters because this cancer subtype is notoriously difficult to treat and kills faster than other breast cancers.
Researchers working on hard-to-treat cancers turned to Munronia henryi, a plant that produces complex defensive compounds called limonoids. From this species, they isolated two previously unknown compounds and found one, named DHL-11, particularly potent against triple-negative breast cancer (TNBC). The work was published in Acta Pharmaceutica Sinica B in October 2025.
What makes this discovery notable isn't just that DHL-11 kills cancer cells—it's how it does it. Instead of blocking an enzyme's main control point (the typical drug strategy), DHL-11 attaches to an overlooked pocket on a protein called IMPDH2 and breaks its partnership with another protein called FANCI. This seemingly small disruption triggers a cascade: the IMPDH2 protein falls apart, guanine production drops, reactive oxygen species accumulate, and DNA damage spirals beyond what the cancer cell can repair. It's like pulling a single thread that unravels the entire survival system.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxIn laboratory tests, DHL-11 slowed cancer cell growth, blocked their ability to spread, and pushed cells toward programmed death. The compound worked not just in simple cell cultures but in patient-derived organoids—three-dimensional tissue models grown from actual cancer samples that preserve features real tumors have. In mice carrying human TNBC tumors, DHL-11 reduced both tumor growth and metastasis while showing a favorable safety profile.
Triple-negative breast cancer earned its ominous name because it lacks three common receptors that other breast cancers have, making targeted drugs largely ineffective. Patients with TNBC face worse outcomes and fewer options than those with other subtypes. A new mechanism of attack, especially one that works through an unconventional pathway, could open a different therapeutic door.
The compound is still in the early laboratory stage—years away from human trials at minimum. But the specificity of DHL-11's action (it targets IMPDH2-positive cancers) and its multi-pronged effect suggest it could become a new class of therapy called a protein degrader, which forces cancer cells to dispose of proteins they depend on. The next phase will be determining whether this promise translates to clinical benefit and whether the compound can be refined or synthesized at scale.
DHL-11, a novel prieurianin-type limonoid isolated from Munronia henryi, targeting IMPDH2 to inhibit triple-negative breast cancer - Acta Pharmaceutica Sinica B, October 2025
